Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X:
”Pre-emptive rituximab stopped relapses in our iTTP patients.
After 3-5 prior relapses each and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 – 68 months)
This is a big deal for a tough disease. Grateful to my mentor, Dr. Khawandanah and our team. More studies are needed, but hope is here.
Super thankful to all of our mentor – Dr James N George, truly a difference maker in these patients, and in his mentees’ careers.
The fellows at OU Health Stephenson Cancer Center continue to shine; we have the best leadership and the fellowship program director (Dr. Sami Ibrahimi).”
Keep up with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers